CLL Research

The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis (2023)
Journal Article
Molica, S., Allsup, D., Polliack, A., & Giannarelli, D. (2023). The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis. European Journal of Haematology, 110(6), 774-777. https://doi.org/10.1111/ejh.13943

Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention (2022)
Journal Article
Khan, S., Molica, S., & Allsup, D. (2022). Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention. Hematological Oncology, https://doi.org/10.1002/hon.3011

Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia (2021)
Journal Article
Khan, S., Durairaj, S., Phumphukhieo, P., Holding, S., & Allsup, D. (2021). Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Leukemia & Lymphoma, 1-8. https://doi.org/10.1080/10428194.2021.1885662